• Explore /
  • Poster
  • / A phase II study of capecitabine plus concomitant radiation therapy followed by durvalumab (MEDI4736) as preoperative treatment in rectal cancer: PANDORA study final results.

A phase II study of capecitabine plus concomitant radiation therapy followed by durvalumab (MEDI4736) as preoperative treatment in rectal cancer: PANDORA study final results.

Abstract Poster

Authors

null

Stefano Tamberi

UOC Oncologia Ravenna, AUSL Romagna, Ravenna, Italy

Stefano Tamberi , Elisa Grassi , Chiara Zingaretti , Giorgio Papiani , Sara Pini , Jody Corbelli , Maria Di Bartolomeo , Filippo Pietrantonio , Giovanni Luca Frassineti , Alessandro Passardi , Fabio Gelsomino , Marina Marzola , Maria Banzi , Andrea Vincent Bonetti , Elisabetta Petracci , Chiara Carli Moretti , Isabella Banchelli , Davide Tassinari , Giampaolo Ugolini , Oriana Nanni

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Gastrointestinal Cancer—Colorectal and Anal

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer - Neo-Adjuvant/Adjuvant

Clinical Trial Registration Number

NCT04083365

Citation

J Clin Oncol 40, 2022 (suppl 17; abstr LBA3513)

DOI

10.1200/JCO.2022.40.17_suppl.LBA3513

Abstract #

LBA3513

Poster Bd #

307

Abstract Disclosures

Similar Posters

First Author: Stefano Tamberi

Poster

2022 ASCO Gastrointestinal Cancers Symposium

Phase II study of durvalumab following neoadjuvant chemoRT in operable rectal cancer: NSABP FR-2.

Phase II study of durvalumab following neoadjuvant chemoRT in operable rectal cancer: NSABP FR-2.

First Author: Thomas J. George

First Author: Daniel Helbling

First Author: Fulong Wang